Jurkat, Clone E6-1

Description

Jurkat, Clone E6-1 is a human acute T-cell leukemia cell line originally established from the peripheral blood of a 14-year-old male patient with T-cell lymphoblastic leukemia. This suspension-growing lymphoblast-like cell line exhibits rapid proliferation. Cytogenetic analysis reveals a pseudodiploid karyotype (modal chromosome number 46) with recurrent abnormalities including deletions in chromosomes 2p21-p23 and 18p11.2, alongside mutations such as the TEL-JAK2 fusion gene and a frameshift mutation in Syk kinase that abolishes protein expression. The cells express CD3 surface markers and demonstrate interleukin-2 (IL-2) production. While primarily utilized for in vitro research, this cell line has been employed in subcutaneous xenograft models of leukemia.

Application

• Jurkat, Clone E6-1 cells are used to investigate T-cell receptor signaling pathways, including CD3/CD28 co-stimulation and calcium-dependent NFAT activation. These cells serve as models for studying HIV latency mechanisms through engineered HIV-infected clones, enabling evaluation of viral reactivation and antiretroviral drug efficacy. The cell line is employed in preclinical screening of kinase inhibitors targeting JAK/STAT signaling abnormalities caused by TEL-JAK2 fusions. In immunotherapy development, Jurkat E6-1 derivatives modified with chimeric antigen receptors (CARs) test cytotoxic T-cell activation protocols. Xenograft models using this line assess leukemia progression in immunodeficient mice.